Type 1 diabetes
Autoimmune beta-cell attack↓
Also searched as Autoimmune beta-cell attack.
You want it prevented, never 'treated' by a supplement: anyone with type 1 needs insulin, and nothing on this page changes that.
In depth
Type 1 diabetes — not a lifestyle disease and not a milder version of type 2. The immune system destroys the insulin-producing cells, and insulin becomes a daily requirement for life.
What drives it
Islet inflammation increases it.
Verbatim: 'Type 1 diabetes results from autoimmune destruction of insulin-producing beta cells' (NBK604182). Seroconversion to islet autoantibodies - IAA, GAD, IA-2, ZnT8 - marks the process years before diagnosis. insulitis is necessary but the timeline is variable; not everyone who seroconverts progresses at the same rate.
Protects insulin cells reduces it.
Beta-cell loss is the disease, not a risk factor for it. Verbatim: type 1 is 'a chronic autoimmune disease caused by progressive selective destruction of pancreatic beta-cells producing insulin' (doi 10.3390/nu11092158). The link runs inversely: preserved beta-cell mass means less type 1 - the residual-secretion 'honeymoon' phase is exactly this edge. doi 10.3390/nu11092158
Vitamin D status reduces it.
Verbatim: 'The pooled odds ratio for type 1 diabetes comparing vitamin D supplementation with non-supplementation during early life was 0.71 (95% CI, 0.51-0.98)' (PMC3798920), eight observational studies. Scope, stated plainly: all eight ARE observational, and the meta's own cohort subgroup was null. Daisy and DIPP found no association with islet autoimmunity. The significant result is on the binary diagnosis endpoint, the nulls are on the earlier seroconversion endpoint. Both stand. PMC3798920
Autoantibodies increases it.
Verbatim: 'Seroconversion is an important marker of the type 1 diabetes disease process' (NBK604182). ENDIT recruited on exactly this basis - '552 relatives with confirmed islet cell antibody (ICA) levels of 20 JDF units or more'. seroconversion predicts but does not guarantee; progression rate varies, and the number of antibodies detected changes the risk.
Insulin production marker reduces it.
Preserved residual secretion is the realistic goal in established type 1. Verbatim: 'about 80% of children and adolescents experience a partial remission, reducing insulin demands to maintain euglycemia. Afterwards, a resumption of the autoimmune process determines a progressive growth of insulin requirements and brings the so-called honeymoon phase of T1D to an end' (doi 10.3390/nu11092158). The link runs inversely: more residual C-peptide means less disease burden - it does not mean the disease is reversed, and it never removes the need for insulin. doi 10.3390/nu11092158
Regulatory T cells reduces it.
Tolerance is the counterweight to the whole disease process. Gut-primed Tregs 'contribute to systemic immune regulation through migration and compartmental redistribution', and microbial tryptophan metabolites activating AHR 'supports pTreg differentiation and interleukin-22-mediated epithelial barrier maintenance' (doi 10.3390/ijms27114789). mechanistic and largely murine; the human Treg literature in type 1 is observational. doi 10.3390/ijms27114789
Pancreatic inflammation increases it.
The link that joins the two halves of this blend. Verbatim: 'Here, we review the literature regarding a potential common aetiological role of pancreatic fibrosis in the pathogenesis of type 3c, type 2 and type 1 diabetes... We propose a second diabetogenic perpetual cycle comprising paracrine signaling between activated pancreatic stellate cells, macrophages and the islets themselves, leading to potentially reversible beta cell failure' (Diabetologia, doi 10.1007/s00125-026-06678-6). This is a review proposing a hypothesis - the authors' own verbs are 'potential' and 'we propose'. The type 3c link is established; the type 1 link is proposed. REFUTED ON A SECOND READING. This link was shown by linked steps until a source was opened that does not support it: “Chronic pancreatitis (CP) progressively destroys pancreatic parenchyma and predisposes patients to pancreatogenic type 3c diabetes mellitus (T3cDM).” — Chronic pancreatitis and pancreatogenic type 3c diabetes risk: a systematic review and meta-analysis. Therapeutic Advances in Endocrinology and Metabolism, 2026, 17. doi 10.1007/s00125-026-06678-6
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.